Clinical score can guide PRRT therapy decisions for neuroendocrine tumors
Peptide receptor radionuclide therapy (PRRT) with lutetium dotatate is a treatment for well-differentiated neuroendocrine tumors that the U.S. Food and Drug Administration approved in 2018, […]
Read more